Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-masked comparison of SB15 vs Eylea in neovascular age-related macular degeneration
jRCT2080225300Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Aug 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sonidegib and aflibercept in exudative macular degeneration (3 arms), sponsored by Samsung Bioepis. Primary endpoint: Change from baseline in best-corrected visual acuity (BCVA) at Week 8. Started Aug 2020; status: completed.
02
Drugs
sonidegibaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2080225300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225300.